This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Lakewood-Amedex Biotherapeutics's Enterprise Value for the quarter that ended in Mar. 2026 was $0.00 Mil.
Lakewood-Amedex Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakewood-Amedex Biotherapeutics EV-to-EBIT Related Terms
Lakewood-Amedex Biotherapeutics EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Lakewood-Amedex Biotherapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lakewood-Amedex Biotherapeutics EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lakewood-Amedex Biotherapeutics's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Lakewood-Amedex Biotherapeutics's EV-to-EBIT falls into.
Lakewood-Amedex Biotherapeutics's current Enterprise Value is $7.96 Mil.
Lakewood-Amedex Biotherapeutics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.46 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lakewood-Amedex Biotherapeutics (LABT) has a EV-to-EBIT of -2.30 as of Jun. 27, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lakewood-Amedex Biotherapeutics and its competitors. According to the industry distribution chart, Lakewood-Amedex Biotherapeutics ranks #999999 out of 373 companies in the Biotechnology industry.
Is Lakewood-Amedex Biotherapeutics' EV-to-EBIT too high?
Lakewood-Amedex Biotherapeutics' current EV-to-EBIT is -2.30. Based on the distribution chart, Lakewood-Amedex Biotherapeutics ranks #999999 out of 373 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Lakewood-Amedex Biotherapeutics has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Lakewood-Amedex Biotherapeutics' EV-to-EBIT compare to CURX and PBM?
According to the Biotechnology industry distribution chart, Lakewood-Amedex Biotherapeutics ranks #999999 out of 373 companies for EV-to-EBIT. This places Lakewood-Amedex Biotherapeutics in the lower half of its industry. The industry median EV-to-EBIT is 14.11. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 14.11, based on 373 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Lakewood-Amedex Biotherapeutics and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 14.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lakewood-Amedex Biotherapeutics's current EV-to-EBIT is -2.30. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lakewood-Amedex Biotherapeutics stock overvalued right now?
Lakewood-Amedex Biotherapeutics (LABT) has a current EV-to-EBIT of -2.30. The current EV-to-EBIT is -2.30. Lakewood-Amedex Biotherapeutics' overall GF Score™ is 8/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Lakewood-Amedex Biotherapeutics (LABT), the current EV-to-EBIT is -2.30 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Lakewood-Amedex Biotherapeutics Business Description
Lakewood-Amedex Biotherapeutics Inc is a clinical-stage biotechnology company developing a novel class of fast-acting, broad-spectrum antimicrobials - the Bisphosphocin class - to treat infectious diseases and reduce the threat posed by antibiotic-resistant bacterial strains, including MRSA, VRE, and others. The company's main product is Nu-3, a topically delivered antimicrobial gel in Phase 2 clinical trials for the treatment of mildly infected diabetic foot ulcers (iDFU). It is also advancing a portfolio of early-stage pipeline compounds developed from its Bisphosphocin platform targeting potential disease indications, including complicated urinary tract infection (cUTI) and pulmonary infections.
8GF Score
Get the complete analysis for LABT
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LABT has been successfully added to your 